Keith Michael Gottesdiener
CIK 1615856 · See Remarks · last filed 2025-09-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$71.82M
Companies
4
Total Filings
36
Lifetime Open-Market Net
-$2.40M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SEPN | Director | — | $38.83 | — | $0 | 1 | 2025-09-29 |
| PRME | See Remarks | 2,361,078 | $3.08 | $7.27M | $0 | 8 | 2025-05-12 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 32,830 | $19.00 | $623.8K | $74.9K | 9 | 2023-05-25 |
| RYTM | CEO & President | 558,250 | $115.63 | $64.55M | -$2.48M | 17 | 2020-03-11 |
Recent Filings · Page 3 of 4
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-03-15 | RYTM | Sell (S) | −9,288 | -$279.2K | EDGAR |
| 2019-02-28 | RYTM | Sell (S) | −2,449 | -$73.6K | EDGAR |
| 2019-02-20 | RYTM | Sell (S) | −12,920 | -$387.9K | EDGAR |
| 2019-02-15 | RYTM | Mixed | −3,934 | -$118.0K | EDGAR |
| 2019-01-24 | RYTM | Sell (S) | −15,779 | -$474.2K | EDGAR |
| 2019-01-22 | RYTM | Sell (S) | −10,115 | -$303.6K | EDGAR |
| 2019-01-17 | RYTM | Sell (S) | −662 | -$19.9K | EDGAR |
| 2018-12-06 | RYTM | Sell (S) | −563 | -$16.9K | EDGAR |
| 2018-11-06 | RYTM | Sell (S) | −16,500 | -$496.3K | EDGAR |
| 2018-06-22 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +1,787 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.